# **RESEARCH ARTICLE**

**Open Access** 

# FP-ADMET: a compendium of fingerprint-based ADMET prediction models

Vishwesh Venkatraman<sup>\*</sup>

# Abstract

**Motivation:** The absorption, distribution, metabolism, excretion, and toxicity (ADMET) of drugs plays a key role in determining which among the potential candidates are to be prioritized. In silico approaches based on machine learning methods are becoming increasing popular, but are nonetheless limited by the availability of data. With a view to making both data and models available to the scientific community, we have developed FPADMET which is a repository of molecular fingerprint-based predictive models for ADMET properties.

**Summary:** In this article, we have examined the efficacy of fingerprint-based machine learning models for a large number of ADMET-related properties. The predictive ability of a set of 20 different binary fingerprints (based on substructure keys, atom pairs, local path environments, as well as custom fingerprints such as all-shortest paths) for over 50 ADMET and ADMET-related endpoints have been evaluated as part of the study. We find that for a majority of the properties, fingerprint-based random forest models yield comparable or better performance compared with traditional 2D/3D molecular descriptors.

**Availability:** The models are made available as part of open access software that can be downloaded from https://gitlab.com/vishsoft/fpadmet.

Keywords: ADMET, Machine learning, Molecular fingerprints

# Introduction

Properties such as absorption, distribution, metabolism, excretion and toxicity (ADMET), are an important component of pharmaceutical drug design. It is often reported that the failure to meet requisite ADMET criteria are a common cause for the high attrition rates of drug candidates [1]. Early ADMET profiling is indeed desirable so as to mitigate the risk of attrition. Various medium and high-throughput in vitro ADMET screens have therefore been developed, that have contributed to the available experimental data. These are nonetheless quite expensive especially when thousands of compounds are involved. Furthermore, reducing animal testing has now become a priority.

\*Correspondence: vishwesh.venkatraman@ntnu.no Norwegian University of Science and Technology, Realfagbygget, Gløshaugen, Høgskoleringen, 7491 Trondheim, Norway



Among the popular services, ADMETLab [12] offers 53 prediction models that are calculated using a multi-task graph attention network and operates on graph-structured data. The method is able to generate customized fingerprints from the general features



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

for a specific task. Another web tool, SwissADME [9] evaluates pharmacokinetics, drug-likeness of small molecules. The predictions are based on a combination of fragmental methods (for solubility), as well as machine-learning based binary classification methods for other ADMET properties (cytochrome-P450 inhibitor, P-glycoprotein substrate). In ADMETSar [11], models for applications in both drug discovery and environmental risk assessment are built using MACCS and Morgan fingerprints. The toxicity models used in ProTox [13] are developed based on chemical similarities between compounds with known toxic effects and the presence of toxic fragments. Other models for hepatotoxicity, cytotoxicity, mutagenicity, and carcinogenicity rely on fingerprints (MACCS/ Morgan). Extended connectivity fingerprints form the basis for the prediction of 15 ADMET properties in the vNN server [10] where models are trained using variable nearest neighbourhood method. pkCSM [6], on the other hand, uses graph-based signatures to develop predictive models of central ADMET properties. Other software such as MDCKPred [14], CarcinoPred-EL [15], CapsCarcino [16] focus on a single property such as the prediction of permeability coefficient and carcinogenic compounds. Overall, the molecular representations underlying these models include various molecular and physicochemical descriptors such as fingerprints, graph signatures, and other 2D/3D indices [17, 18]. Among these, fingerprint representations which are seen as an alternative to descriptors for QSPR studies, have been quite popular given their ease of computation and predictive value.

A number of fingerprints ranging from substructure/path to feature-class/circular have been proposed many of which are used in similarity searching [19, 20]. For ADMET studies however, the fingerprints studied so far have largely been restricted to a select few. In this study, we have evaluated the predictive efficacy of 20 different fingerprints ranging from substructure and extended/functional connectivity fingerprints to various path based encodings (depth-first search, shortest path, local path environments) [21]. The fingerprint-based regression/classification models were calculated for over 50 ADMET and ADMETrelated endpoints (using data collated from various literature sources) and is to our knowledge one of the most comprehensive compilations analysed. For a majority of the endpoints, the prediction results were found to be comparable with more sophisticated descriptor formulations. Although the pharmacophore fingerprints yielded consistently poor results, others such as the PUBCHEM, MACCS and ECFP/ FCFP encodings were found to yield the best results for most properties. The models and related software have been bundled into a downloadable package and is released under the GNU license.

# Approach

## Molecular representation

In this study, we have examined 20 different fingerprints (see Table 1) that are routinely used as similarity search tools in drug discovery. The ECFP- and FCFP-class fingerprints are circular topological fingerprints, where the former focuses on the atom properties (e.g. atomic number, charge, hydrogen count), whereas in the functional connectivity FPs, the emphasis is on properties that relate to ligand binding (e.g. hydrogen donor/acceptor, polarity, aromaticity). MACCS and PUBCHEM fingerprints are substructure fingerprints that cover a wide range of features such as element counts and ring systems, atom pairing, or atom environment etc. Other fingerprints include path based fingerprints such as the depth-first search fingerprints (DFS), all-shortest path encoding (ASP), radial fingerprints (Molprint2D), topological atom pairs (AP2D) and triplets (AT2D), pharmacophore pair and triplet encodings as well as local path environments [21]. Fingerprint calculations were performed using in-house code written in Java and makes use of the Chemistry Development Kit library [22]. The software merges existing fingerprints in the library with those calculated by the software *jCompoundMapper* [21].

**Table 1** Fingerprints used in this study to model different

 ADMET related properties

Fingerprint	Size
MACCS	166
PUBCHEM	881
Klekota-Roth (KR)	4860
MOLPRINT (RAD2D)	4096
Atom pair (AP), atom triplet (AT)	4096
Local path environments (LSTAR)	4096
All-shortest path (ASP)	4096
Depth first search (DFS)	4096
Extended conectivity (ECFP: 0, 2, 4, 6)	1024
Functional class (FCFP: 0, 2, 4, 6)	1024
Pharmacophore: 2PPHAR/3PPHAR (2/3 point)	4096
ESTATE	79

Descriptions and implementation details of the different fingerprints are provided in the article by Hinselmann et al [21] and the references therein

# Table 2 Summary of the ADMET endpoints studied

Endpoint	Model	#Compounds	Group	Data source
Blood brain barrier	BC	7236	Distribution	[3, 31]
Oral bioavailability	BC	1822	Absorption	
Anticommensal effect	BC	1181	Toxicity	[33, 34]
CYP450 (1A2) inhibition	BC	17119	Metabolism	[35]
CYP450 (2C19) inhibition	BC	17119	Metabolism	[35]
CYP450 (2C9) inhibition	BC	17119	Metabolism	[35]
CYP450 (2D6) inhibition	BC	17119	Metabolism	[35]
CYP450 (3A4) inhibition	BC	17119	Metabolism	[35]
CYP450 (2C8) inhibition	BC	533	Metabolism	[36]
HIA	BC	1516	Absorption	[3, 37]
BCRP inhibition	BC	2799	Metabolism	[38]
Metabolic intrinsic clearance	MC	5278	Excretion	[39]
Human liver microsomal stability	BC	3654		[40]
PGP inhibitor	BC	2930	Distribution	[3, 41]
PGP substrate	BC	2198	Distribution	[3, 41]
DMSO solubility	BC	59047		[42]
Phosphate buffer solubility	BC	57584		[43]
Skin sensitization (LLNA)	BC	1033	Toxicity	[44]
Skin sensitization (KeratinSens)	BC	190	Toxicity	[44]
Skin sensitization (HRIPT)	BC	138	Toxicity	[44]
Skin sensitization (h-CLAT)	BC	160	Toxicity	[44]
Skin sensitization (DPRA)	BC	194	Toxicity	[44]
Rat acute oral toxicity (LD <sub>50</sub> )	MC	11363	Toxicity	[3, 45]
AMES mutagenecity	BC	7950	Toxicity	[46]
Cytotoxicity (HepG2)	BC	6081	Toxicity	[10]
Cytotoxicity (CRL-7250 cell line)	BC	5241	Toxicity	[47]
Cytotoxicity (HACAT cell line)	BC	5241	Toxicity	[47]
Cytotoxicity (HEK cell line)	BC	5241	Toxicity	[47]
Cytotoxicity (NIK cell line)	BC	5241	Toxicity	[47]
DILI	BC	2478	Toxicity	[48]
Hemolytic toxicity (saponins)	BC	452	Toxicity	[49]
hERG cardiotoxicity	BC	7889	Toxicity	[50]
hERG liability	BC	9204	,	[51]
Mitochondrial toxicity	BC	6467	Toxicity	[52]
Urinary tract toxicity	BC	213	Toxicity	[53, 54]
Phototoxicity	BC	516	Toxicity	[55]
Phototoxicity	BC	1419	Toxicity	[55]
Toxic myopathy	BC	232	Toxicity	[56]
Myelotoxicity	BC	907	Toxicity	[57]
Phospholipidosis	BC	1719	Toxicity	[58]
Choleostasis	BC	1926	Toxicity	[59]
Rhabdomyolysis	BC	1504	Toxicity	[60]
Respiratory toxicity	BC	1241	Toxicity	[61]
Ototoxicity	BC	2612	Toxicity	[62]
MATE1 inhibition	BC	853	Metabolism	[63]
Hepatic steatosis	BC	512	Toxicity	[64]
Carcinogenecity	BC	1003	Toxicity	[15]
OATP1B1 inhibition	BC	1339	Metabolism	[65]
OATP2B1 inhibition	BC	230	Metabolism	[65]
				,

# Table 2 (continued)

Endpoint	Model	#Compounds	Group	Data source
OATP1B3 inhibition	BC	1249	Metabolism	[65]
BSEP inhibition	BC	1634	Metabolism	[66]
OCT2 inhibition	BC	907	Metabolism	[67]
PPB	MC	8103	Distribution	[3, 68]
Elimination half-life Human	MC	2127	Excretion	[69]
Elimination half-life Mouse	MC	808	Excretion	[69]
Elimination half-life Rat	MC	1308	Excretion	[69]

Here BC and MC refer to binary and multiclass classification respectively

OATP organic anion transporting polypeptide, CYP-450 cytochrome-P450, BCRP breast cancer resistance protein, BSEP bile salt export pump, DILI drug-induced liver injury, OCT organic cation transporter 2, MATE1 multidrug toxin extrusion transporter, hERG human Ether-á-go-go-related gene, HIA human intestinal absorption, PPB plasma protein binding, PGP p-glycoprotein, LLNA local lymph node assay, DPRA direct peptide reactivity assay, h-CLAT human cell line activation, HRIPT human repeat insult patch test, HEK 293 human embryonic kidney 293 cell, MATE1 multidrug and toxin extrusion transporter 1

Table 3 Summary of the ADMET and other endpoints for which fingerprint-based regression models were evaluated

Endpoint	#Compounds	Group	Data source
Aqueous solubility (logS)	9982		[70]
Intrinsic clearance (CL <sub>int</sub> )	244	Excretion	[71]
Skin penetration (log $k_p$ )	211	Toxicity	[72]
Human serum albumin	198		[73, 74]
Human placenta barrier (clearance index)	88	Distribution	[75]
Cancer potency in mouse ( $TD_{50}$ )	402	Toxicity	[76]
Cancer potency in rat ( $TD_{50}$ )	511	Toxicity	[76]
Steady state volume distribution (VD <sub>ss</sub> )	1951	Distribution	[3, 77]
Distribution coefficient (log D)	7321		[3, 78]
Fraction unbound in human plasma	2319	Distribution	[79]
Fraction unbound in the brain	253	Distribution	[80]
Human liver microsomal clearance	5348	Excretion	[30]
Rat liver microsomal clearance	2166	Excretion	[30]
Mouse liver microsomal clearance	790	Excretion	[30]
CACO-2 permeability	2578	Absorption	[30]
рҚ <sub>а</sub>	11041		[81, 82]
MDCK cell line permeability	701	Absorption	[3]
Human renal clearance ( <i>CL<sub>r</sub></i> )	636	Excretion	[83]
Hemolytic toxicity (log HD <sub>50</sub> )	875	Toxicity	[84]

MDCK Madin-Darby canine kidney

### **Data curation**

Data for different endpoints were collected from previously published articles and databases with a primary source being the Online Chemical Database (OCHEM) [3]. The molecules were subsequently cleaned and duplicates (where present) were removed. Tables 2 and 3 lists the various endpoints and associated data sources considered in this study. Brief descriptions of the endpoints and the results from previous modelling efforts are provided in Additional file 1. Since, early identification of severe toxicity is a key requirement for the safety evaluation of drug candidates, we have evaluated a number of toxicity models covering a range of endpoints such as cardiac, hepatotoxicity, endocrine, urinary tract, carcinogenicity and cytotoxicity. While a majority of the models are binary classification models, for some endpoints such the metabolic intrinsic clearance, acute oral toxicity in rats, plasma protein binding and elimination half-life, multiclass models are proposed.

For other endpoints, regression models have been evaluated (see Table 3). These include the CACO-2 permeability which is commonly used to predict the

**Table 4** Performance metrics for the best performingfingerprint-based classification models

Endpoint	FP	Calibration		Validation	
		BACC	AUC	BACC	AUC
Blood brain barrier	PUBCHEM	0.82	0.90	0.81	0.92
Oral bioavailability	PUBCHEM	0.71	0.77	0.71	0.78
Anticommensal effect	PUBCHEM	0.76	0.82	0.74	0.81
CYP450 (1A2)	PUBCHEM	0.85	0.93	0.85	0.93
CYP450 (2C19)	ECFP4	0.81	0.88	0.81	0.89
CYP450 (2C9)	PUBCHEM	0.78	0.88	0.79	0.89
CYP450 (2D6)	FCFP4	0.73	0.86	0.73	0.87
CYP450 (3A4)	FCFP6	0.80	0.89	0.80	0.90
CYP450 (2C8)	PUBCHEM	0.79	0.89	0.77	0.90
HIA	MACCS	0.84	0.89	0.83	0.89
BCRP inhibition	FCFP4	0.89	0.95	0.90	0.96
Metabolic intrinsic clearance	FCFP4	0.74	0.82	0.74	0.84
Human liver microsomal stability	AT2D	0.77	0.83	0.77	0.84
PGP inhibitor	PUBCHEM	0.84	0.91	0.85	0.92
PGP substrate	ASP	0.80	0.87	0.80	0.88
DMSO solubility	ECFP2	0.72	0.78	0.73	0.80
Phosphate buffer solubility	PUBCHEM	0.79	0.87	0.79	0.87
Skin sensitization (LLNA)	PUBCHEM	0.69	0.76	0.67	0.74
Skin sensitization (KeratinSens)	LSTAR	0.64	0.65	0.57	0.60
Skin sensitization (HRIPT)	ECFP0	0.70	0.74	0.67	0.72
Skin sensitization (hCLAT)	MACCS	0.65	0.70	0.61	0.68
Skin sensitization (DPRA)	FCFP4	0.68	0.72	0.68	0.72
Rat acute oral toxicity (LD <sub>50</sub> )	PUBCHEM	0.69	0.78	0.68	0.81
AMES mutagenecity	PUBCHEM	0.79	0.86	0.79	0.87
Cytotoxicity (HepG2)	AT2D	0.78	0.85	0.78	0.85
Cytotoxicity (CRL-7250 cell line)	AT2D	0.79	0.87	0.78	0.86
Cytotoxicity (HACAT cell line)	AT2D	0.77	0.85	0.77	0.85
Cytotoxicity (HEK cell line)	PUBCHEM	0.77	0.87	0.76	0.86
Cytotoxicity (NIK cell line)	PUBCHEM	0.78	0.87	0.78	0.87
DILI	PUBCHEM	0.78	0.86	0.79	0.88
Hemolytic toxicity (saponins)	FCFP6	0.84	0.88	0.85	0.90
hERG cardiotoxicity	FCFP6	0.79	0.86	0.80	0.88
hERG liability	PUBCHEM	0.76	0.87	0.76	0.88
Mitochondrial toxicity	PUBCHEM	0.79	0.90	0.77	0.90
Urinary tract toxicity	FCFP4	0.71	0.77	0.70	0.73
Phototoxicity in vitro	KR	0.70	0.76	0.69	0.80
Phototoxicity human	PUBCHEM	0.69	0.75	0.67	0.75
Toxic myopathy	DFS	0.68	0.74	0.63	0.74
Myelotoxicity	FCFP4	0.72	0.79	0.71	0.80
phospholipidosis	FCFP2	0.78	0.86	0.77	0.88
Cholestasis	RAD2D	0.67	0.73	0.67	0.74
Rhabdomyolysis	MACCS	0.71	0.80	0.70	0.83
Respiratory toxicity	MACCS	0.82	0.88	0.82	0.89
Ototoxicity	PUBCHEM	0.69	0.74	0.67	0.72
MATE1	DFS	0.64	0.67	0.65	0.65
Hepatic steatosis	MACCS	0.63	0.67	0.59	0.68
Carcinogenecity	PUBCHEM	0.67	0.71	0.68	0.75

# Table 4 (continued)

Endpoint	FP Calibration		Validation		
		BACC	AUC	BACC	AUC
OATP1B1 inhibition	ECFP6	0.72	0.80	0.73	0.82
OATP2B1 inhibition	ECFP6	0.67	0.68	0.65	0.70
OATP1B3 inhibition	PUBCHEM	0.74	0.83	0.77	0.87
BSEP inhibition	ECFP4	0.85	0.93	0.88	0.95
OCT2 inhibition	PUBCHEM	0.73	0.81	0.73	0.79
PPB	PUBCHEM	0.82	0.92	0.84	0.92
Elimination half-life Human	ASP	0.75	0.86	0.76	0.88
Elimination half-life Mouse	ECFP2	0.74	0.86	0.72	0.84
Elimination half-life Rat	KR	0.74	0.86	0.74	0.83

The values reported are the balanced accuracies (BACC) and area under the ROC curve (AUC) (average of 3 independent runs) for the calibration/validation sets

absorption of orally administered drugs and other xenobiotics, the fraction of unbound drug in plasma, the liver microsomal clearance (typically used to predict hepatic clearance in humans), in vitro human skin permeability and the cancer potency. Models for other ADMET-related properties have also been studied. For instance, properties such as the dissociation constant ( $pK_a$ ) affect solubility (log S), permeability, distribution coefficient (log D) and oral absorption. These in turn along with other properties such as the human serum albumin (HSA) binding impact pharmacokinetic behaviour and drug bioavailability.

### Modelling

In order to build the models, the Random Forest algorithm [23] was chosen which is an ensemble learning method for both classification and regression. The algorithm makes use of bagging and feature randomness to build multiple decision trees (each trained on a random subset of data) and merges them together. The models were trained using the ranger [24] library in the statistical computing environment  $\mathbb{R}$  [25]. The number of trees used to compute the final average predicted value was set to 500. For each endpoint, the data was split randomly into separate training (80%) and test (20%) sets. A fivefold cross-validation was used to identify the best performing model. In order to rule out any selection bias, we repeated random splitting 3 times and the results were averaged to gain an understanding of the variability. Furthermore, y-randomization tests were conducted to assess the robustness of the final model. To address the problem with unequal distribution of samples between classes, data augmentation of the minority class was carried out using the synthetic minority oversampling technique (SMOTE) [26].

Endpoint	FP	Calibrat	Calibration			Validation	
		R <sup>2</sup>	RMSE	MAE	R <sup>2</sup>	RMSE	MAE
log S	PUBCHEM	0.77	1.15	0.81	0.78	1.12	0.78
Intrinsic clearance (CL <sub>int</sub> )	RAD2D	0.48	0.83	0.65	0.29	1.02	0.82
Skin penetration (log $k_p$ )	PUBCHEM	0.73	0.60	0.48	0.75	0.56	0.43
Human serum albumin	AP2D	0.71	0.33	0.23	0.69	0.39	0.26
Human placenta barrier	KR	0.41	0.24	0.20	0.24	0.32	0.22
Cancer potency in mouse ( $TD_{50}$ )	AT2D	0.33	0.98	0.75	0.27	0.96	0.72
Cancer potency in rat ( $TD_{50}$ )	AT2D	0.41	1.08	0.83	0.35	1.14	0.87
Steady state volume distribution ( $VD_{ss}$ )	ASP	0.58	0.44	0.29	0.45	0.51	0.32
Distribution coefficient (log D)	PUBCHEM	0.76	0.73	0.53	0.77	0.71	0.50
Fraction unbound in human plasma	PUBCHEM	0.60	0.46	0.35	0.63	0.44	0.34
Fraction unbound in the brain	PUBCHEM	0.48	0.58	0.46	0.56	0.56	0.45
Human liver microsomal clearance	KR	0.51	1.08	0.80	0.56	1.05	0.79
Mouse liver microsomal clearance	AT2D	0.52	1.21	0.92	0.53	1.16	0.88
Rat liver microsomal clearance	KR	0.64	1.08	0.83	0.67	1.01	0.76
CACO-2 permeability	FCFP4	0.44	0.68	0.46	0.42	0.69	0.46
рК <sub>а</sub>	ECFP2	0.71	1.85	1.15	0.74	1.78	1.11
MDCK cell line permeability	ECFP4	0.62	0.61	0.44	0.68	0.56	0.39
Human renal clearance	MACCS	0.25	0.54	0.43	0.27	0.53	0.42
Hemolytic toxicity (log $HD_{50}$ )	ASP	0.68	0.47	0.35	0.68	0.44	0.34

 Table 5
 Performance metrics for the best performing fingerprint-based regression models

The values reported are the squared correlation ( $R^2$ ), RMSE and MAE (average of 3 independent runs) for the calibration/validation sets

For regression models, the performance was assessed using the squared regression coefficient ( $R^2$ ) for the correlation between experimental and predicted values. the root mean squared error (RMSE) and the mean absolute error (MAE). For classification models, metrics that are sensitive to the class imbalance have been used. These include the balanced accuracy (BACC) given by:

$$BACC = \frac{1}{m} \sum_{i}^{m} \frac{k_i}{n_i} \tag{1}$$

where  $k_i$  is the number of correct predictions in class *i*, *m* is the number of classes and  $n_i$  is the number of examples in class *i*. In addition, other metrics such as the overall accuracy, the sensitivity (the true positive rate—TPR) and specificity (the true negative rate—TNR) and the area under the curve (AUC) are also reported (see Additional file 1).

Every model has a finite applicability domain (AD) within which its predictions can be trusted. For regression models, we quantify the prediction intervals (95%) using the quantile regression forests approach [27]. Here, a shorter prediction interval indicates the higher stability of prediction. In the case of classification, two values: confidence and credibility are associated with the predicted label based on

the conformal prediction framework [28, 29]. While the confidence provides a measure of how likely a prediction is compared to all other possible classifications, the credibility measure (equal to the highest *p*-value of any one of the possible classifications being the true label) provides an indication of how good the training set is for classifying the given example.

### **Results and discussion**

For the various endpoints, the relevant performance metrics associated with the best fingerprint-based models are summarized in Tables 4 (for classification models) and 5 (for regression models). The complete performance summary for the training and validations sets is listed in Additional file 1: Tables S1 and S2. For all cases, permutation tests confirmed (p-values < 0.001) that the probability that the model was obtained by chance is quite low. Overall, high classification accuracies (BACC > 0.80) are obtained for the blood brain barrier permeability, plasma protein binding, CYP450 inhibition (3A4/2C19/1A2/2C9/2C8 isoforms), human intestinal absorption, breast cancer resistance protein inhibition, p-glycoprotein inhibitor/ substrate and hemolytic/respiratory toxicity. For some of the other endpoints such as the mitochondrial/urinary tract toxicity, human liver microsomal stability,



metabolic intrinsic clearance, AMES mutagenecity, cytotoxicity (multiple cell lines), hERG cardiotoxicity/ liability, drug induced liver injury, myelotoxicity, phospholipidosis, rhabdomyolysis, OATP1B1/OATP1B3 inhibition, BSEP and OCT2 inhibition, moderate (BACC = 0.71 to -0.78) performances were observed. Properties such as skin sensitization, acute oral toxicity, phototoxicity in humans, ototoxicity, choleostasis, hepatic steatosis, and carcinogenecity yielded somewhat average results. In the case of regression models, performances were largely on the poorer side with the exception of  $pK_a$ , log S, log D, human serum albumin and skin penetration,  $R_{cv}^2 > 0.70$ .

To identify which of the fingerprints perform well on the different datasets, we plotted heatmaps (see Figs. 1 and 2) of the balanced accuracies (for classification models) and squared correlations (in the case of regression) obtained for the different endpoints. While the pharmacaphore fingerprints (2PPHAR/3PPHAR) perform poorly on all datasets, fingerprints based on substructure keys (PUBCHEM, MACCS, KR) show moderate to high accuracies for a majority of the modelled endpoints. Although the performances for regression models are somewhat less encouraging, here too the  $R_{cv}^2$  for PUBCHEM, ECFP4, and ASP fingerprints yield better models than the other fingerprints tested.

We further compared the performances achieved by the fingerprint models with those obtained for the 2D/3D descriptor based approaches. The barplots in Fig. 3 compare the accuracies achieved by the fingerprint models with values reported by the models published earlier. While results for most properties are comparable, for some endpoints such as myelotoxicity, ototoxicity, myopathy accuracies obtained using 2D/3D descriptors are only marginally better. Indeed better results are obtained for rhabdomyolysis, phospholipidosis, phototoxicity with other descriptor based models. For phototoxicity in particular, quantum chemistry-based 3D descriptors are used which can add to the time taken. It must however be pointed out that some of the better performing models take advantage of deep learning. Attempts to improve results for selected properties were carried out using support vector machines. However, the models were not always found to improve on the random forest approach.

For the regression models calculated for selected properties:  $pK_a$ , log S, log D, skin penetration, human serum albumin, MDCK permeability  $HD_{50}$ , we assessed the prediction reliability based on the prediction intervals. Plots of the prediction intervals with respect to the observed response values for the test sets (see Additional file 1: Figure S1) showed that most of the samples lie within the 95% prediction interval which indicates that the constructed prediction intervals are reliable. For classification models, we focused on excluding compounds whose labels are predicted with low confidence and credibility. Thus, different thresholds for p-values (0.5, 0.6, 0.7, 0.8, 0.9) were applied and the corresponding fraction of molecules that would be withheld from further testing was recorded. A plot of the overall error rates and the percentage reduction in compounds excluded from further processing (see Additional file 1: Figure S2) shows that for many of the endpoints modelled, the predictive performance is not significantly impacted even at cutoffs of 0.50. Such a strategy that allows for compound selection based on static thresholds for the confidence/credibility offer a way to reduce the number of compounds that typically undergo experimental testing.



### Software usage

FP-ADMET is available as open access software (GNU GPL v3.0) and can be downloaded from https://gitlab. com/vishsoft/fpadmet. Use of FP-ADMET proceeds in two steps (i) fingerprint calculation followed by (ii) predicting the ADMET endpoint of interest. The software is command line driven and is governed by a shell script (*runadmet.sh*) that can be run as:

bash runadmet.sh -f molecule.smi -p
## -a

The input to the script is a file (*molecule.smi*) containing SMILES strings. The ## is a number between 1 (predict Anticommensal Effect) and 56 (predict skin penetration) and corresponds to the prediction task. The results are written to a text file where each line contains molecule name and the predicted response. The "-a" option allows for the calculation of prediction intervals (in the case of regression) and confidence (for classification). For classification, conformal prediction is used to calculate a confidence (how certain the model is that the prediction is a singleton) and a credibility. For example, predicting AMES mutagenecity (task number 4) for a series of molecules produces the following results (see Table 6). The label "inactive" for compound G00001 suggests that the compound is predicted to be non-mutagenic. A confidence value of 0.95 suggests that the classifier is quite certain that the prediction is likely to be a single label. A relatively low value of credibility (0.57) suggests that the compounds like G00001 are not sufficiently represented in the training set and that the user needs to treat the prediction with caution. In the case of regression, a 95% prediction interval (predictions at the 0.025 and 97.5 percentiles for  $pK_a$ ) is calculated and provides a range for the predictions on an individual observation.

**Table 6** Example showing the property ( $pK_a$  and anticommensal effect) predictions and associated uncertainties for 3 molecules

Name	Anticommensal effect	Confidence	Credibility	pĥa	Q=0.025	Q=0.975
G00001	Inactive	0.95	0.57	9.62	4.89	11.49
G00002	Active	0.95	0.51	4.41	- 1.60	13.06
G00003	Inactive	0.95	0.57	3.37	1.66	6.10

Q = 0.025 and Q = 0.975 are the predictions calculated at percentiles 0.025 and 0.975 and allow for 95% prediction intervals



Narrow prediction intervals indicate a lower uncer-

tainty associated with the prediction.

# Conclusion

In this article, we have evaluated the performance of various molecular fingerprints for predicting a number of ADMET and ADMET-related endpoints. A total of 1500 models were analysed spanning 75 responses and 20 fingerprints. The results show that the machine learning performance using the different fingerprint encodings rival those of traditional descriptor-based methods. Future work will focus on combining different data sets in a multitask modeling approach which has been shown to yield statistically superior results compared with single-task models [12, 30]. In order to facilitate ADMET evaluation, the best performing models have been compiled into an open access software package called FPADMET that can be downloaded from https://gitlab.com/vishsoft/ fpadmet.

# **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s13321-021-00557-5.

Additional file 1. File contains brief descriptions of the properties modelled, additional performance statistics and figures referred to in the text.

### Acknowledgements

The author thanks Dr. Amitava Roy (NIH) and Assoc. Prof. Travis Wheeler (University of Montana) for fruitful discussions.

### Authors' contributions

W conceived and designed the study, performed the data analysis and wrote the paper. The author read and approved the final manuscript.

### Funding

This work was supported through a grant (Grant No. 262152) from the Research Council of Norway.

# Declarations

### **Competing interests**

The authors declare that they have no competing interests.

Received: 7 April 2021 Accepted: 20 September 2021 Published online: 28 September 2021

### References

- Ferreira LLG, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today 24(5):1157–1165. https://doi.org/10. 1016/j.drudis.2019.03.015
- Kar S, Leszczynski J (2020) Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov 15(12):1473–1487. https://doi.org/10.1080/17460441.2020.1798926
- Sushko I, Novotarskyi S, Körner R, Pandey AK, Rupp M, Teetz W, Brandmaier S, Abdelaziz A, Prokopenko VV, Tanchuk VY, Todeschini R, Varnek A, Marcou G, Ertl P, Potemkin V, Grishina M, Gasteiger J, Schwab C, Baskin II, Palyulin VA, Radchenko EV, Welsh WJ, Kholodovych V, Chekmarev D, Cherkasov A, Aires-de-Sousa J, Zhang Q-Y, Bender A, Nigsch F, Patiny L, Williams A, Tkachenko V, Tetko IV (2011) Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des 25(6):533–554. https://doi.org/10.1007/s10822-011-9440-2
- Guan L, Yang H, Cai Y, Sun L, Di P, Li W, Liu G, Tang Y (2019) ADMETscore—a comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm 10(1):148–157. https://doi.org/10.1039/ c8md00472b
- Jia C-Y, Li J-Y, Hao G-F, Yang G-F (2020) A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discov Today 25(1):248–258. https://doi.org/10.1016/j.drudis.2019.10.014
- Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: predicting smallmolecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072. https://doi.org/10.1021/acs. jmedchem.5b00104
- Clark AM, Dole K, Coulon-Spektor A, McNutt A, Grass G, Freundlich JS, Reynolds RC, Ekins S (2015) Open source Bayesian models. 1. Application to ADME/Tox and drug discovery datasets. J Chem Inf Model 55(6):1231– 1245. https://doi.org/10.1021/acs.jcim.5b00143
- Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO (2017) FAFdrugs4: free ADME-Tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics 33(22):3658–3660. https://doi. org/10.1093/bioinformatics/btx491
- Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. https://doi.org/10.1038/srep42717
- Schyman P, Liu R, Desai V, Wallqvist A (2017) vNN web server for ADMET predictions. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00889
- Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, Li W, Liu G, Tang Y (2018) admet-SAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 35(6):1067–1069. https://doi.org/10.1093/bioin formatics/bty707
- 12. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D (2021) ADMETIab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 49(W1):5–14. https://doi.org/10.1093/nar/gkab255
- Banerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46(W1):257– 263. https://doi.org/10.1093/nar/gky318
- Patel RD, Kumar SP, Pandya HA, Solanki HA (2018) MDCKpred: a webtool to calculate MDCK permeability coefficient of small molecule using membrane-interaction chemical features. Toxicol Mech Methods 28(9):685–698. https://doi.org/10.1080/15376516.2018.1499840
- Zhang L, Ai H, Chen W, Yin Z, Hu H, Zhu J, Zhao J, Zhao Q, Liu H (2017) CarcinoPred-EL: novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods. Sci Rep. https://doi.org/10.1038/s41598-017-02365-0
- Wang Y-W, Huang L, Jiang S-W, Li K, Zou J, Yang S-Y (2020) CapsCarcino: a novel sparse data deep learning tool for predicting carcinogens. Food Chem Toxicol 135:110921. https://doi.org/10.1016/j.fct.2019.110921
- Yap CW (2010) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comp Chem 32(7):1466–1474. https://doi.org/10.1002/jcc.21707

- Venkatraman V, Alsberg BK (2016) KRAKENX: software for the generation of alignment-independent 3D descriptors. J Mol Model. https://doi.org/ 10.1007/s00894-016-2957-5
- Muegge I, Mukherjee P (2015) An overview of molecular fingerprint similarity search in virtual screening. Expert Opin Drug Discov 11(2):137–148. https://doi.org/10.1517/17460441.2016.1117070
- Cereto-Massagué A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallvé S, Pujadas G (2015) Molecular fingerprint similarity search in virtual screening. Methods 71:58–63. https://doi.org/10.1016/j.ymeth.2014.08.005
- Hinselmann G, Rosenbaum L, Jahn A, Fechner N, Zell A (2011) jCompoundMapper: an open source java library and command-line tool for chemical fingerprints. J Cheminf. https://doi.org/10.1186/1758-2946-3-3
- Willighagen EL, Mayfield JW, Alvarsson J, Berg A, Carlsson L, Jeliazkova N, Kuhn S, Pluskal T, Rojas-Chertó M, Spjuth O, Torrance G, Evelo CT, Guha R, Steinbeck C (2017) The chemistry development kit (CDK) v2.0: atom typing, depiction, molecular formulas, and substructure searching. J Cheminf. https://doi.org/10.1186/s13321-017-0220-4
- 23. Breiman L (2001) Random forests. Mach Learn 45(1):5–32. https://doi.org/ 10.1023/a:1010933404324
- Wright MN, Ziegler A (2017) ranger: a fast implementation of random forests for high dimensional data in C++ and R. J Stat Soft 77(1):1–17. https://doi.org/10.18637/jss.v077.i01
- 25. R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. R Foundation for Statistical Computing. https://www.R-project.org/
- Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP (2002) SMOTE synthetic minority over-sampling technique. J Artif Intell Res 16:321–357. https:// doi.org/10.1613/jair.953
- 27. Meinshausen N (2006) Quantile regression forests. J Mach Learn Res 7(35):983–999
- Papadopoulos H (2008) Chap. 18. Inductive conformal prediction: theory and application to neural networks. In: Fritzsche P (ed) Tools in artificial intelligence. IntechOpen, Rijeka. https://doi.org/10.5772/6078
- Ahlberg E, Hammar O, Bendtsen C, Carlsson L (2017) Current application of conformal prediction in drug discovery. Ann Math Artif Intell 81(1–2):145–154. https://doi.org/10.1007/s10472-017-9550-1
- Wenzel J, Matter H, Schmidt F (2019) Predictive multitask deep neural network models for ADME-Tox properties: learning from large data sets. J Chem Inf Model 59(3):1253–1268. https://doi.org/10.1021/acs.jcim.8b007 85
- Shaker B, Yu M-S, Song JS, Ahn S, Ryu JY, Oh K-S, Na D (2020) LightBBB: computational prediction model of blood–brain-barrier penetration based on LightGBM. Bioinformatics. https://doi.org/10.1093/bioinforma tics/btaa918
- Falcón-Cano G, Molina C, Cabrera-Pérez MÁ (2020) ADME prediction with KNIME: development and validation of a publicly available workflow for the prediction of human oral bioavailability. J Chem Inf Model 60(6):2660–2667. https://doi.org/10.1021/acs.jcim.0c00019
- Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555(7698):623–628. https://doi.org/10.1038/nature25979
- 34. Zheng S, Chang W, Liu W, Liang G, Xu Y, Lin F (2018) Computational prediction of a new ADMET endpoint for small molecules: anticommensal effect on human gut microbiota. J Chem Inf Model 59(3):1215–1220. https://doi.org/10.1021/acs.jcim.8b00600
- Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N, Shen M, Inglese J, Austin CP, Lloyd DG, Auld DS (2009) Comprehensive characterization of cytochrome p450 isozyme selectivity across chemical libraries. Nat Biotechnol 27(11):1050–1055. https://doi.org/10.1038/nbt.1581
- Zhang X, Zhao P, Wang Z, Xu X, Liu G, Tang Y, Li W (2021) In silico prediction of CYP2c8 inhibition with machine-learning methods. Chem Res Toxicol 34(8):1850–1859. https://doi.org/10.1021/acs.chemrestox.1c00078
- Wang N-N, Huang C, Dong J, Yao Z-J, Zhu M-F, Deng Z-K, Lv B, Lu A-P, Chen AF, Cao D-S (2017) Predicting human intestinal absorption with modified random forest approach: a comprehensive evaluation of molecular representation, unbalanced data, and applicability domain issues. RSC Adv 7(31):19007–19018. https://doi.org/10.1039/c6ra28442f
- Jiang D, Lei T, Wang Z, Shen C, Cao D, Hou T (2020) ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein

inhibition through machine learning. J Cheminf. https://doi.org/10. 1186/s13321-020-00421-y

- Esaki T, Watanabe R, Kawashima H, Ohashi R, Natsume-Kitatani Y, Nagao C, Mizuguchi K (2018) Data curation can improve the prediction accuracy of metabolic intrinsic clearance. Mol Inf 38(1–2):1800086. https://doi.org/10.1002/minf.201800086
- Liu R, Schyman P, Wallqvist A (2015) Critically assessing the predictive power of QSAR models for human liver microsomal stability. J Chem Inf Model 55(8):1566–1575. https://doi.org/10.1021/acs.jcim.5b00255
- Wang P-H, Tu Y-S, Tseng YJ (2019) PgpRules: a decision tree based prediction server for p-glycoprotein substrates and inhibitors. Bioinformatics 35(20):4193–4195. https://doi.org/10.1093/bioinformatics/ btz213
- Tetko IV, Novotarskyi S, Sushko I, Ivanov V, Petrenko AE, Dieden R, Lebon F, Mathieu B (2013) Development of dimethyl sulfoxide solubility models using 163000 molecules: using a domain applicability metric to select more reliable predictions. J Chem Inf Model 53(8):1990–2000. https://doi.org/10.1021/ci400213d
- Perryman AL, Inoyama D, Patel JS, Ekins S, Freundlich JS (2020) Pruned machine learning models to predict aqueous solubility. ACS Omega 5(27):16562–16567. https://doi.org/10.1021/acsomega.0c01251
- Borba JVB, Braga RC, Alves VM, Muratov EN, Kleinstreuer N, Tropsha A, Andrade CH (2020) Pred-skin: a web portal for accurate prediction of human skin sensitizers. Chem Res Toxicol. https://doi.org/10.1021/acs. chemrestox.0c00186
- Gadaleta D, Vuković K, Toma C, Lavado GJ, Karmaus AL, Mansouri K, Kleinstreuer NC, Benfenati E, Roncaglioni A (2019) SAR and QSAR modeling of a large collection of LD50 rat acute oral toxicity data. J Cheminf. https:// doi.org/10.1186/s13321-019-0383-2
- Xu C, Cheng F, Chen L, Du Z, Li W, Liu G, Lee PW, Tang Y (2012) In silico prediction of chemical Ames mutagenicity. J Chem Inf Model 52(11):2840–2847. https://doi.org/10.1021/ci300400a
- Sun H, Wang Y, Cheff DM, Hall MD, Shen M (2020) Predictive models for estimating cytotoxicity on the basis of chemical structures. Bioorg Med Chem 28(10):115422. https://doi.org/10.1016/j.bmc.2020.115422
- Mora JR, Marrero-Ponce Y, García-Jacas CR, Causado AS (2020) Ensemble models based on QuBiLS-MAS features and shallow learning for the prediction of drug-induced liver toxicity: improving deep learning and traditional approaches. Chem Res Toxicol 33(7):1855–1873. https://doi. org/10.1021/acs.chemrestox.0c00030
- Zheng S, Wang Y, Liu W, Chang W, Liang G, Xu Y, Lin F (2019) In silico prediction of hemolytic toxicity on the human erythrocytes for small molecules by machine-learning and genetic algorithm. J Med Chem 63(12):6499–6512. https://doi.org/10.1021/acs.jmedchem.9b00853
- Cai C, Guo P, Zhou Y, Zhou J, Wang Q, Zhang F, Fang J, Cheng F (2019) Deep learning-based prediction of drug-induced cardiotoxicity. J Chem Inf Model 59(3):1073–1084. https://doi.org/10.1021/acs.jcim.8b00769
- Siramshetty VB, Nguyen D-T, Martinez NJ, Southall NT, Simeonov A, Zakharov AV (2020) Critical assessment of artificial intelligence methods for prediction of hERG channel inhibition in the "big data" era. J Chem Inf Model 60(12):6007–6019. https://doi.org/10.1021/acs.jcim.0c00884
- Hemmerich J, Troger F, Füzi B, Ecker FG (2020) Using machine learning methods and structural alerts for prediction of mitochondrial toxicity. Mol Inf 39(5):2000005. https://doi.org/10.1002/minf.202000005
- Lei T, Sun H, Kang Y, Zhu F, Liu H, Zhou W, Wang Z, Li D, Li Y, Hou T (2017) ADMET evaluation in drug discovery. 18. Reliable prediction of chemicalinduced urinary tract toxicity by boosting machine learning approaches. Mol Pharm 14(11):3935–3953. https://doi.org/10.1021/acs.molpharmac eut.7b00631
- Zhang H, Ren J-X, Ma J-X, Ding L (2018) Development of an in silico prediction model for chemical-induced urinary tract toxicity by using Naïve Bayes classifier. Mol Divers 23(2):381–392. https://doi.org/10.1007/ s11030-018-9882-8
- Schmidt F, Wenzel J, Halland N, Güssregen S, Delafoy L, Czich A (2019) Computational investigation of drug phototoxicity: photosafety assessment, photo-toxophore identification, and machine learning. Chem Res Toxicol 32(11):2338–2352. https://doi.org/10.1021/acs.chemrestox.9b003 38
- Hu X, Yan A (2011) In silico models to discriminate compounds inducing and noninducing toxic myopathy. Mol Inf 31(1):27–39. https://doi.org/10. 1002/minf.201100067

- Zhang H, Yu P, Zhang T-G, Kang Y-L, Zhao X, Li Y-Y, He J-H, Zhang J (2015) In silico prediction of drug-induced myelotoxicity by using Naïve Bayes method. Mol Divers 19(4):945–953. https://doi.org/10.1007/ s11030-015-9613-3
- Fusani L, Brown M, Chen H, Ahlberg E, Noeske T (2017) Predicting the risk of phospholipidosis with in silico models and an image-based in vitro screen. Mol Pharm 14(12):4346–4352. https://doi.org/10.1021/acs.molph armaceut.7b00388
- Kotsampasakou E, Ecker GF (2017) Predicting drug-induced cholestasis with the help of hepatic transporters—an in silico modeling approach. J Chem Inf Model 57(3):608–615. https://doi.org/10.1021/acs.jcim.6b00518
- Cui X, Liu J, Zhang J, Wu Q, Li X (2019) In silico prediction of drug-induced rhabdomyolysis with machine-learning models and structural alerts. J Appl Toxicol 39(8):1224–1232. https://doi.org/10.1002/jat.3808
- Zhang H, Ma J-X, Liu C-T, Ren J-X, Ding L (2018) Development and evaluation of in silico prediction model for drug-induced respiratory toxicity by using Naïve Bayes classifier method. Food Chem Toxicol 121:593–603. https://doi.org/10.1016/j.fct.2018.09.051
- Zhang H, Liu C-T, Mao J, Shen C, Xie R-L, Mu B (2020) Development of novel in silico prediction model for drug-induced ototoxicity by using Naïve Bayes classifier approach. Toxicol In Vitro 65:104812. https://doi.org/ 10.1016/j.tiv.2020.104812
- Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47a1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 56(3):781–795. https://doi.org/10.1021/jm301302s
- 64. Jain S, Norinder U, Escher SE, Zdrazil B (2020) Combining in vivo data with in silico predictions for modeling hepatic steatosis by using stratified bagging and conformal prediction. Chem Res Toxicol. https://doi.org/10. 1021/acs.chemrestox.0c00511
- 65. Türková A, Jain S, Zdrazil B (2018) Integrative data mining, scaffold analysis, and sequential binary classification models for exploring ligand profiles of hepatic organic anion transporting polypeptides. J Chem Inf Model 59(5):1811–1825. https://doi.org/10.1021/acs.jcim.8b00466
- McLoughlin KS, Jeong CG, Sweitzer TD, Minnich AJ, Tse MJ, Bennion BJ, Allen JE, Calad-Thomson S, Rush TS, Brase JM (2021) Machine learning models to predict inhibition of the bile salt export pump. J Chem Inf Model 61(2):587–602. https://doi.org/10.1021/acs.jcim.0c00950
- Kido Y, Matsson P, Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug–drug interactions mediated by the organic cation transporter 2. J Med Chem 54(13):4548–4558. https://doi. org/10.1021/jm2001629
- Yuan Y, Chang S, Zhang Z, Li Z, Li S, Xie P, Yau W-P, Lin H, Cai W, Zhang Y, Xiang X (2020) A novel strategy for prediction of human plasma protein binding using machine learning techniques. Chemom Intell Lab Syst 199:103962. https://doi.org/10.1016/j.chemolab.2020.103962
- Podlewska S, Kafel R (2018) MetStabOn—online platform for metabolic stability predictions. Int J Mol Sci 19(4):1040. https://doi.org/10.3390/ ijms19041040
- Sorkun MC, Khetan A, Er S (2019) AqSolDB, a curated reference set of aqueous solubility and 2D descriptors for a diverse set of compounds. Sci Data. https://doi.org/10.1038/s41597-019-0151-1
- Hsiao Y-W, Fagerholm U, Norinder U (2013) In silico categorization of in vivo intrinsic clearance using machine learning. Mol Pharm 10(4):1318– 1321. https://doi.org/10.1021/mp300484r
- Lindh M, Karlén A, Norinder U (2017) Predicting the rate of skin penetration using an aggregated conformal prediction framework. Mol Pharm 14(5):1571–1576. https://doi.org/10.1021/acs.molpharmaceut.7b00007
- Serra A, Önlü S, Coretto P, Greco D (2019) An integrated quantitative structure and mechanism of action-activity relationship model of human serum albumin binding. J Cheminf. https://doi.org/10.1186/ s13321-019-0359-2
- 74. Ciura K, Ulenberg S, Kapica H, Kawczak P, Belka M, Bączek T (2020) Drug affinity to human serum albumin prediction by retention of cetyltrimethylammonium bromide pseudostationary phase in micellar electrokinetic chromatography and chemically advanced template search descriptors. J Pharm Biomed 188:113423. https://doi.org/10.1016/j.jpba.2020.113423
- 75. Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A (2009) Application of quantitative structure activity relationships for modeling drug and chemical transport across the human placenta barrier: a multivariate data

analysis approach. J Appl Toxicol 29(8):724–733. https://doi.org/10.1002/ jat.1466

- Bercu JP, Morton SM, Deahl JT, Gombar VK, Callis CM, van Lier RBL (2010) In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances. Regul Toxicol Pharmacol 57(2):300–306. https://doi.org/10.1016/j.yrtph.2010.03.010
- Simeon S, Montanari D, Gleeson MP (2019) Investigation of factors affecting the performance of in silico volume distribution QSAR models for human, rat, mouse, dog & monkey. Mol Inf 38(10):1900059. https://doi. org/10.1002/minf.201900059
- Fu L, Liu L, Yang Z-J, Li P, Ding J-J, Yun Y-H, Lu A-P, Hou T-J, Cao D-S (2019) Systematic modeling of *logD*<sub>7</sub>.4 based on ensemble machine learning, group contribution, and matched molecular pair analysis. J Chem Inf Model 60(1):63–76. https://doi.org/10.1021/acs.jcim.9b00718
- Watanabe R, Esaki T, Kawashima H, Natsume-Kitatani Y, Nagao C, Ohashi R, Mizuguchi K (2018) Predicting fraction unbound in human plasma from chemical structure: improved accuracy in the low value ranges. Mol Pharm 15(11):5302–5311. https://doi.org/10.1021/acs.molpharmaceut. 8b00785
- Esaki T, Ohashi R, Watanabe R, Natsume-Kitatani Y, Kawashima H, Nagao C, Mizuguchi K (2019) Computational model to predict the fraction of unbound drug in the brain. J Chem Inf Model 59(7):3251–3261. https:// doi.org/10.1021/acs.jcim.9b00180

- Lu Y, Anand S, Shirley W, Gedeck P, Kelley BP, Skolnik S, Rodde S, Nguyen M, Lindvall M, Jia W (2019) Prediction of pK<sub>a</sub> using machine learning methods with rooted topological torsion fingerprints: application to aliphatic amines. J Chem Inf Model 59(11):4706–4719. https://doi.org/10. 1021/acs.jcim.9b00498
- Mansouri K, Cariello NF, Korotcov A, Tkachenko V, Grulke CM, Sprankle CS, Allen D, Casey WM, Kleinstreuer NC, Williams AJ (2019) Open-source QSAR models for pKa prediction using multiple machine learning approaches. J Cheminf. https://doi.org/10.1186/s13321-019-0384-1
- Chen J, Yang H, Zhu L, Wu Z, Li W, Tang Y, Liu G (2020) In silico prediction of human renal clearance of compounds using quantitative structurepharmacokinetic relationship models. Chem Res Toxicol 33(2):640–650. https://doi.org/10.1021/acs.chemrestox.9b00447
- Zheng S, Xiong J, Wang Y, Liang G, Xu Y, Lin F (2020) Quantitative prediction of hemolytic toxicity for small molecules and their potential hemolytic fragments by mach. learn. and recursive fragmentation methods. J Chem Inf Model 60(6):3231–3245. https://doi.org/10.1021/acs.jcim.0c001 02

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

